Blood, IL-5 and IL-13 production from MLNs and splenocytes, and AHR.

Blood, IL-5 and IL-13 production from MLNs and splenocytes, and AHR. Confirming our previous data [16], we again found that these features of AHR were suppressed by the administration of KSpn. We first detected substantial increases in Tlr2 and Tlr4 gene expression in the lung during KSpn-mediated suppression of AAD. Then in AAD we identified inductive roles for: TLR2 in IL-5 release from MLN T cells, IL-5 and IL13 release from splenocytes and AHR; TLR4 in eosinophil infiltration into BALF and blood (partial) and AHR, and; MyD88 in blood eosinophilia, IL-13 release from MLN T cells and AHR (Fig 7). In addition, in the absence of both TLR2 and TLR4 there was actually an increasePLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,9 /TLRs in Suppression of Allergic Airways DiseaseFig 5. Airway responsiveness at baseline and hyperresponsiveness in AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88-/-, TLR2-/-, TLR4-/- and TLR2/4-/- mice were order U0126-EtOH BMS-986020 cancer sensitized and challenged with OVA to induce AAD. AHR in terms of airway resistance and dynamic compliance in saline sensitized mice (A). AHR in terms of airway resistance and dynamic compliance in OVA sensitized mice (B). Data represent mean ?SEM, n = 8. Significance is represented by ��P < 0.01, ���P < 0.001 (Wt v -/between Saline groups) and P < 0.01, P < 0.001 (Wt v -/- between OVA groups). doi:10.1371/journal.pone.0156402.gin the release of IL-13 from MLN T cells. This is relevant since local IL-13 release can induce all of the features of AAD/asthma [37?9]. In KSpn-mediated suppression of AAD we identified important suppressive roles for: TLR2 in eosinophil infiltration into the airways (partial) and AHR; TLR4 in eosinophilia of the airways and blood, IL-5 and IL-13 release from splenocytes and AHR, and; MyD88 in airway and blood eosinophilia and AHR (Fig 7). Furthermore, data from TLR2/4-/- mice showed that both these TLRs were required for the suppression of eosinophils in BALF due to the absence of TLR4, and blood due to the absence of TLR2. Collectively, these data indicate that KSpn, and its components, can be used in immunoregulatory approaches to suppress AAD, which occurs through the induction of protective TLR responses. This provides further evidence for the use of these and other TLR agonists as asthma therapies [11]. Our analysis of mRNA expression in the lung in AAD showed that only that of Tlr4 mRNA was increased, and then only during sensitization. However, TLR2 and TLR4 mRNA expression was up-regulated by KSpn, which occurred during sensitization (Tlr2 and Tlr4) and challenge (Tlr4). This shows potential roles for TLR4 in allergic sensitization and that both these TLRs are involved in KSpn-mediated suppression of AAD. Furthermore, it indicates the existence of a positive feedback loop where KSpn-induced TLR engagement can lead to increased TLR expression that may be protective in AAD. This is known to occur with the TLR4 ligand lipopolysaccharide, which up-regulates TLR2 in a MyD88-dependent manner [40], and withPLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,10 /TLRs in Suppression of Allergic Airways DiseaseFig 6. Airway responsiveness at baseline and hyperresponsiveness in KSpn-induced suppression of AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88-/-, TLR2-/-, TLR4-/- and TLR2/4-/- mice were sensitized and challenged with OVA to induce AAD. Some groups were administered KSpn i.t. during sensitization. The effect of KSpn on AHR in terms of airw.Blood, IL-5 and IL-13 production from MLNs and splenocytes, and AHR. Confirming our previous data [16], we again found that these features of AHR were suppressed by the administration of KSpn. We first detected substantial increases in Tlr2 and Tlr4 gene expression in the lung during KSpn-mediated suppression of AAD. Then in AAD we identified inductive roles for: TLR2 in IL-5 release from MLN T cells, IL-5 and IL13 release from splenocytes and AHR; TLR4 in eosinophil infiltration into BALF and blood (partial) and AHR, and; MyD88 in blood eosinophilia, IL-13 release from MLN T cells and AHR (Fig 7). In addition, in the absence of both TLR2 and TLR4 there was actually an increasePLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,9 /TLRs in Suppression of Allergic Airways DiseaseFig 5. Airway responsiveness at baseline and hyperresponsiveness in AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88-/-, TLR2-/-, TLR4-/- and TLR2/4-/- mice were sensitized and challenged with OVA to induce AAD. AHR in terms of airway resistance and dynamic compliance in saline sensitized mice (A). AHR in terms of airway resistance and dynamic compliance in OVA sensitized mice (B). Data represent mean ?SEM, n = 8. Significance is represented by ��P < 0.01, ���P < 0.001 (Wt v -/between Saline groups) and P < 0.01, P < 0.001 (Wt v -/- between OVA groups). doi:10.1371/journal.pone.0156402.gin the release of IL-13 from MLN T cells. This is relevant since local IL-13 release can induce all of the features of AAD/asthma [37?9]. In KSpn-mediated suppression of AAD we identified important suppressive roles for: TLR2 in eosinophil infiltration into the airways (partial) and AHR; TLR4 in eosinophilia of the airways and blood, IL-5 and IL-13 release from splenocytes and AHR, and; MyD88 in airway and blood eosinophilia and AHR (Fig 7). Furthermore, data from TLR2/4-/- mice showed that both these TLRs were required for the suppression of eosinophils in BALF due to the absence of TLR4, and blood due to the absence of TLR2. Collectively, these data indicate that KSpn, and its components, can be used in immunoregulatory approaches to suppress AAD, which occurs through the induction of protective TLR responses. This provides further evidence for the use of these and other TLR agonists as asthma therapies [11]. Our analysis of mRNA expression in the lung in AAD showed that only that of Tlr4 mRNA was increased, and then only during sensitization. However, TLR2 and TLR4 mRNA expression was up-regulated by KSpn, which occurred during sensitization (Tlr2 and Tlr4) and challenge (Tlr4). This shows potential roles for TLR4 in allergic sensitization and that both these TLRs are involved in KSpn-mediated suppression of AAD. Furthermore, it indicates the existence of a positive feedback loop where KSpn-induced TLR engagement can lead to increased TLR expression that may be protective in AAD. This is known to occur with the TLR4 ligand lipopolysaccharide, which up-regulates TLR2 in a MyD88-dependent manner [40], and withPLOS ONE | DOI:10.1371/journal.pone.0156402 June 16,10 /TLRs in Suppression of Allergic Airways DiseaseFig 6. Airway responsiveness at baseline and hyperresponsiveness in KSpn-induced suppression of AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88-/-, TLR2-/-, TLR4-/- and TLR2/4-/- mice were sensitized and challenged with OVA to induce AAD. Some groups were administered KSpn i.t. during sensitization. The effect of KSpn on AHR in terms of airw.